Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 4/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 3/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL862619 | 0.95 | SMPD1 (0.41) | SMPD1ESR1THRATHRBALOX5 | |
| SCHEMBL12252238 | 0.94 | ESR1 (0.43) | ESR1CYP3A4THRATHRB | |
| SCHEMBL862517 | 0.94 | ESR1 (0.43) | ESR1CYP3A4THRATHRB | |
| SCHEMBL10153565 | 0.93 | SMPD1 (0.36) | SMPD1ESR1HMGCRCYP3A4THRA | |
| SCHEMBL862614 | 0.91 | ESR1 (0.42) | ESR1CYP3A4THRATHRB | |
| SCHEMBL10153468 | 0.89 | SMPD1 (0.37) | SMPD1ESR1THRATHRBALOX5 | |
| SCHEMBL13759588 | 0.88 | HMGCR (0.47) | SMPD1ESR1HMGCRCYP3A4THRA | |
| SCHEMBL13030818 | 0.88 | HMGCR (0.47) | SMPD1ESR1HMGCRCYP3A4THRA | |
| SCHEMBL14570394 | 0.88 | HMGCR (0.47) | SMPD1ESR1HMGCRCYP3A4THRA | |
| SCHEMBL13607213 | 0.88 | CYP1A1 (0.43) | SMPD1CYP1A1CYP1B1CYP1A2NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8142908-B2 | Polymer light-emitting material comprising a conjugated polymer and compound exhibiting light emission from the triplet excited state and polymer light-emitting device using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-03-27 | — | — | US | disclosed |
| US-8012603-B2 | Polyanilines; strong fluorescence and large charge transporting properties | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20080138651-A1 | Polyanilines; strong fluorescence and large charge transporting properties | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-06-12 | — | — | US | disclosed |
| US-20070051922-A1 | Polymer light-emitting material and polymer light-emitting device | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20070040164-A1 | Polymer complex compound and polymer light emitting device using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-02-22 | — | — | US | disclosed |
| US-7157154-B2 | Organoboron polymers; photoconductivity; inks; thin films; semiconductors; surface light sources; dot matrix displays | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080138651-A1 | Polyanilines; strong fluorescence and large charge transporting properties | BRS3, SLC43A1, MRPS23 | SMPD1 4418/4885ESR1 1141/4885HMGCR 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.